Lifeforce Capital
Lifeforce Capital is a San Francisco-based venture capital firm founded in 2015 that invests in healthcare software companies across Care Delivery and Techbio verticals, managing a portfolio of 50+ companies and recording six notable exits including One Medical and Clover Health IPOs.
- Company typePrivate
- Founded2015
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Lifeforce Capital does
Lifeforce Capital is a San Francisco-based venture capital firm founded in 2015 that invests in software companies reshaping healthcare's largest markets. The firm operates with a small team of 1-10 employees under Managing Partner John Noonan and structures its portfolio around two thematic pillars: Care Delivery, encompassing companies advancing new technologies and care models (e.g., Cityblock Health for Medicaid care delivery, HeartFlow for cardiovascular care, Eko Health for digital health); and Techbio, comprising software-first biotech platforms driving a paradigm shift away from traditional biotechnology (e.g., Aspen Neuroscience for cell therapy, Enveda Bio, Serna Bio, Postera for AI-driven drug discovery). The firm manages a portfolio of more than 50 companies and has recorded six notable exits, including IPOs for One Medical ($ONEM) and Clover Health ($CLOV), and acquisitions of Able Health by Health Catalyst, Aspire Healthcare by Anthem, Cricket Health by InterWell Health, and TARA Biosystems by Valo Health.
Lifeforce Capital's business model follows standard venture capital economics, generating revenue through management fees on assets under management and carried interest on successful portfolio exits, though specific fund sizes, AUM, and LP composition are not publicly disclosed. The firm operates with a lean partnership structure, relying on its website (lifeforcecap.com) and a fund panel portal (fundpanel.io/LifeforceCapital) for LP relations and portfolio visibility. Capital deployment is concentrated exclusively in healthcare software and biotech, providing deep domain specialization rather than broad market exposure. The firm targets growth-stage software companies in healthcare's largest markets that seek both capital and strategic support, differentiating through its thematic focus on care delivery innovation and techbio platform shifts rather than competing on check size or sector breadth.
The underlying "product" Lifeforce Capital offers is portfolio construction and value-add support — convening healthcare founders, providing industry expertise, and syndicating with other healthcare-focused investors. Technology infrastructure at the firm level is minimal and not publicly disclosed; the firm does not appear to operate proprietary deal-sourcing platforms, data analytics engines, or in-house research publications that would constitute a technology moat beyond its investment track record.
Lifeforce Capital firmographics
Firmographics- Name
- Lifeforce Capital
- Legal name
- Lifeforce Capital
- Website
- https://lifeforcecap.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lifeforce Capital is a San Francisco-based venture capital firm founded in 2015 that invests in healthcare software companies across Care Delivery and Techbio verticals, managing a portfolio of 50+ companies and recording six notable exits including One Medical and Clover Health IPOs.
- Ownership category
- akta.pro rank
Lifeforce Capital industry classification
Industry- Product category
- Venture Capital / Healthcare Investment
- NAICS
- Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where Lifeforce Capital is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Lifeforce Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Distribution channels1 record
Marketing channels1 record
Lifeforce Capital product offering
Product offeringCore offering
Lifeforce Capital is a venture capital firm that invests growth capital in software companies reshaping healthcare's largest markets. Its portfolio is organized around two theses: Care Delivery (companies advancing care through new technologies and care models) and Techbio (software-first platforms driving a paradigm shift away from traditional biotechnology). Revenue is generated through investment returns, exits, and fund management.
Product overview
Lifeforce Capital is a venture capital firm that invests in software companies reshaping healthcare's largest markets. The firm focuses on two main investment categories: Care Delivery companies that advance care through new technologies and care models, and Techbio companies that drive a paradigm shift away from traditional biotechnology with software-first platforms. Lifeforce Capital does not appear to offer its own distinct product or service offering; rather, it operates as an investment vehicle with a portfolio of portfolio companies across healthcare technology, biotech, and care delivery sectors. The company's portfolio includes notable exits such as Able Health (acquired by Health Catalyst), Aspire Healthcare (acquired by Anthem), Clover Health (IPO), Cricket Health (acquired by InterWell Health), One Medical (IPO), and TARA Biosystems (acquired by Valo Health).
Differentiator
Problem solved
Functional benefit
Products and services
- Care Delivery Venture Investments Growth-stage venture capital investments in software companies that advance healthcare care delivery through new technologies and care models. Target investments include companies operating in care delivery transformation, such as Cityblock Health, HeartFlow, Eko Health, Advantia Health, Bayesian Health, Belle AI, and similar healthcare software platforms.
- Techbio Venture Investments Growth-stage venture capital investments in software-first biotech companies that drive a paradigm shift away from traditional biotechnology through computational and platform approaches. Target investments include companies such as 64xBio, Aspen Neuroscience, Enveda Bio, Fauna Bio, Ochre Bio, Sonoma Bio, Reverie Labs, and Verge Genomics.
- LP Fund Portal Access Limited partner reporting and relations portal hosted at fundpanel.io for Lifeforce Capital's fund investors. Provides LPs with portfolio visibility and fund administration.
Companies that use Lifeforce Capital
Customer profileSegments1 record
Ideal customer profiles2 records
Lifeforce Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lifeforce Capital partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights3 records
Lifeforce Capital competitors and assessment
Company assessmentDirect peers
- Venrock: Long-standing early-stage VC with a deep healthcare focus, investing across digital health, therapeutics, and care delivery — closely aligned with Lifeforce's Care Delivery and biotech orientation.
- Oak HC/FT: Healthcare and fintech specialist VC writing growth and early-stage checks; comparable to Lifeforce as a vertical-focused firm backing software-driven transformation of healthcare services.
- Foresite Capital: Healthcare-dedicated VC investing across therapeutics, diagnostics, and digital health — a direct comparable on Lifeforce's Care Delivery and Techbio thesis.
- ARCH Venture Partners: Premier life sciences and healthcare-tech investor backing early-stage biotech and techbio platforms; highly comparable to Lifeforce's biotech-heavy portfolio companies.
- Section 32: Healthcare-only venture fund investing across digital health, biotech, and care delivery — comparable specialist positioning and stage orientation to Lifeforce.
Broad incumbents
- Andreessen Horowitz (a16z Bio): Large multi-stage VC with a dedicated bio/health fund investing across care delivery, digital health, and biotech — overlaps Lifeforce's thesis but at materially greater scale and check size.
- General Catalyst: Multi-stage VC with a strong healthcare transformation practice (e.g., Cityblock Health, One Medical) — directly overlaps with Lifeforce's Care Delivery thesis but at much broader scale.
- Khosla Ventures: Broad VC with significant healthcare and techbio exposure across digital health and AI-driven therapeutics — competes for similar early-stage healthcare deals as Lifeforce.
- Bessemer Venture Partners: Multi-stage VC with a substantial healthcare practice across care delivery, biotech, and healthtech SaaS — a broader, more diversified competitor for healthcare-software deals.
- GV (Google Ventures): Multi-stage VC with deep healthcare and life sciences investing across digital health and biotech — competes for the same category-defining companies Lifeforce targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Lifeforce Capital social profiles
Digital presenceLifeforce Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lifeforce Capital leadership team
Management profileNumber of profiles
Profiles1 record
Lifeforce Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lifeforce Capital M&A and investment
M&A and investmentM&A
Investments60 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lifeforce Capital
What does Lifeforce Capital do?
Lifeforce Capital is a venture capital firm that invests growth capital in software companies reshaping healthcare's largest markets. Its portfolio is organized around two theses: Care Delivery (companies advancing care through new technologies and care models) and Techbio (software-first platforms driving a paradigm shift away from traditional biotechnology). Revenue is generated through investment returns, exits, and fund management.
Is Lifeforce Capital a public or private company?
Lifeforce Capital is a private company. It is classified as unknown and is currently operating.
When was Lifeforce Capital founded?
Lifeforce Capital was founded in 2015. It employs 1 to 10 people.
Where is Lifeforce Capital based?
Lifeforce Capital is headquartered in San Francisco, United States, in the North America region.
Who are Lifeforce Capital's main competitors?
Direct peers on record are Venrock, Oak HC/FT, Foresite Capital, ARCH Venture Partners and Section 32. Broad incumbents are Andreessen Horowitz (a16z Bio), General Catalyst, Khosla Ventures, Bessemer Venture Partners and GV (Google Ventures).
Does Lifeforce Capital have an API?
No public API is recorded for Lifeforce Capital.
What industry is Lifeforce Capital in?
Lifeforce Capital's product category is Venture Capital / Healthcare Investment. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 52394 and its SIC code is 6282.